Ignite Creation Date:
2024-05-06 @ 8:29 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06391944
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-30
First Post:
2024-04-26
Brief Title:
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer NSCLC Characterized by Epithermal Growth Factor Receptor EGFR Common Mutations
Sponsor:
Shanghai JMT-Bio Inc
Organization:
Shanghai JMT-Bio Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-11-21
Start Date Type:
ACTUAL
Primary Completion Date:
2023-05-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-11-21
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-26
First Submit QC Date:
April 26 2024
Study First Post Date:
2024-04-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-26
Last Update Post Date:
2024-04-30
Last Update Post Date Type:
ACTUAL